This roundtable series evaluates genomic testing and NTRK-targeted treatment in patients with thyroid cancer as discussed by participants at virtual live events.
Larotrectinib Shows High Efficacy in Differentiated Thyroid Cancer
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.
Sequencing Treatments for NTRK-Positive Thyroid Cancer
Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.
Response to Larotrectinib in NTRK+ Thyroid Cancer Differs By Subtype
Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.
Targeting NTRK Fusions in Advanced NSCLC Leads Deep Responses
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a patient with NTRK fusion–positive cancer.